Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas. Show more

1017 Ranch Road 620 South, Lakeway, TX, 78734, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

17.73M

52 Wk Range

$0.43 - $3.42

Previous Close

$0.43

Open

$0.42

Volume

56,391

Day Range

$0.42 - $0.44

Enterprise Value

31.14M

Cash

9.042M

Avg Qtr Burn

-1.313M

Insider Ownership

40.84%

Institutional Own.

54.45%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Selonabant (ANEB-001) Details Cannabinoid intoxication	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IV Selonabant (ANEB-001) Details Cannabinoid intoxication	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.